• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Niche Markets and Rare Diseases: Bladder Cancer Product Image

Niche Markets and Rare Diseases: Bladder Cancer

  • Published: December 2011
  • Region: World
  • 177 Pages
  • Decision Resources, Inc

The bladder is the fourth most common tumor site among all tumors that can afflict both genders. However, because of its very high risk of recurrence and its frequent presentation as multiple tumors within the bladder, bladder cancer represents a healthcare burden disproportionate to its incidence. Few new agents have been approved for BC in the past 20 years, which is in marked contrast to many other tumor types, where monoclonal antibodies and kinase inhibitors have led to gains in survival.

Thus, the competitive barriers to entry remain much lower in BC than in some other cancer markets. BC research has suffered from a lack of funding, but now several of the top pharmaceutical developers are investing in developing treatments for bladder cancer; five new agents are poised for approval for use in bladder cancer over the next ten years.

1. Executive Summary
Key Parameters of the Bladder Cancer Market
Drivers
Constraints
Drug Development Activity
What Do The Experts Say?
Key Challenges & Opportunities

2. Clinical Context
Disease Burden
Staging of Tumors According to Depth of Invasion
TNM Staging
Clinical Staging
Recurrent Disease
Etiology
Pathophysiology
Emerging Drug Targets
Physician Opinion on Etiology and Pathophysiology

3. Patient Populations
Patient Populations: Overview
Disease Definition
Estimation Methods and Sources
Diagnosed Incident Cases
10-Year Prevalent Cases
Drug-Treatable Populations
Methods: Newly Diagnosed Incident Cases
Methods: Recurrent Incident Cases
Methods: Prevalent Cases
Methods: Stage Distribution

4. Current Therapies and Medical Practice
Disease Prevention and Screening
Referral Patterns
Trends in Cystoscopy and Cytology
Trends in Diagnostic Imaging
Treatment Providers
Treatment Guidelines
Physicians’ Perceptions of Clinical Guidelines: United States
Physicians’ Perceptions of Clinical Guidelines: Europe
Commonly Prescribed Drugs
Drugs Approved for BC
Mechanism of Action Analysis
Clinical Trial End Points
Treatment by Stage: NMIBC
Treatment After Recurrent or Progressive NMIBC
Treatment Algorithm for NMIBC
Clinical Analysis of Therapies Used to Treat NMIBC
Toxicity of Therapies Used to Treat NMIBC
Adherence to NMIBC Clinical Guidelines: United States
Adherence to NMIBC Clinical Guidelines: Europe
Devices Used to Treat NMIBC
Treatment by Stage: MIBC
Treatment Algorithm for MIBC
Clinical Analysis of Therapies Used to Treat MIBC
Toxicity of Therapies Used to Treat MIBC
MIBC Adjuvant vs. Neoadjuvant Chemotherapy
Adherence to MIBC Clinical Guidelines
Treatment by Stage: MBC
Treatment Algorithm for MBC
Clinical Analysis of Therapies Used to Treat MBC

5. Opportunities and Emerging Therapies
Status of Investigational Targeted Agents
Status of Investigational Immuno- and Chemotherapies
Unmet Needs: Overview
Unmet Needs: Therapies Based on Specific Tumor Biology
Unmet Needs: Novel Therapies for NMIBC
Unmet Needs: Therapies That Extend OS in MBC
Unmet Needs: Increased Investment and Collaboration
Orphan Drug Provisions
Agents Poised to Reach the Market by 2015
Agents Poised to Reach the Market by 2020
Emerging Therapies by Setting
Mechanism of Action Analysis
Comparison of Emerging Therapies Across Tumor Types

Format Properties
Electronic (PDF) The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.
Note: Product cover images may vary from those shown
More

RELATED PRODUCTS

Our Clients

Our clients' logos